They were shown to target eIF4A1 and eIF4A2, to potently inhibit translation and tumor cell viability, and are effective in synergizing with DNA-damaging agents in vivo against the MYC (proto-oncogene)-driven lymphomas (Chu et al. 2019). Here, EIF4A2 is linked to neoplasm.